IL1B and chronic kidney disease: Indirect suppression of IL-1β signaling by a caspase 1 inhibitor belnacasan (also known as VX-765) has been shown to ameliorate kidney damage and fibrosis in experimental AKI and CKD models but these beneficial effects may be also related to inhibition of pyroptosis (111–113).